| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Original Article |
1 Department of Surgery-Colorectal Service, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, Room C-1077, New York, New York 10021
2 Department of Pathology, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, Room M-616, New York, New York 10021
3 Department of Radiation Oncology, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, Room S-M06, New York, New York 10021
Correspondence: Address correspondence and reprint requests to: Jose G. Guillem, MD, MPH; E-mail: guillemj{at}mskcc.org
Background: Preoperative combined-modality therapy (CMT) is the preferred treatment for locally advanced rectal cancer (endorectal ultrasonography [ERUS] T3–4, N1, or clinically bulky) and achieves a pathologic complete response (pCR) in 4% to 33% of patients. However, the prognostic significance of pCR remains unclear.
Methods: A prospectively collected database was queried to identify 200 patients with locally advanced disease treated from 1992 to 2002. The pCR group was defined as having no evidence of viable tumor on pathologic analysis. The no-downstaging group was defined as no difference between the pre-CMT ERUS stage and the pathologic stage. Those achieving some downstaging but not pCR were excluded. Patients were treated with CMT (5040 cGy of radiation and 5-fluorouracil–based chemotherapy) followed by surgery, and 51 (85%) in the pCR group and 129 (92%) in the no-downstaging group (P = .1) received postoperative chemotherapy. Recurrence-free survival (RFS) and overall survival (OS) were determined by using the Kaplan-Meier method.
Results: The median follow-up was 38.6 months (range, 18.2–124.9 months). The pCR (n = 60) and control (n = 140) groups were similar in age (P = .6), sex (P = .4), distance of the tumor from the anal verge (P = .3), pre-CMT ERUS stage (P = .2), and comorbidities (P = .2). The 5-year RFS was 96% and 54% in the pCR and control groups, respectively (P < .00001); the 5-year OS was 90% and 68% (P = .009). Sphincter-preservation rates were higher in the pCR group (P = .01).
Conclusions: Rectal cancer patients with pCR after preoperative CMT have improved RFS, OS, and sphincter preservation compared with patients without downstaging. Because pCR seems to be associated with better outcome, an understanding of the factors governing the response to CMT should be pursued.
Key Words: Rectal cancer • Radiotherapy • Pathologic response • Combined modality therapy • Oncologic outcome
This article has been cited by other articles:
 |
|
 |
|
  A. S. Caudle, H. J. Kim, J. E. Tepper, B. H. O'Neil, L. A. Lange, R. M. Goldberg, S. A. Bernard, B. F. Calvo, and M. O. Meyers Diabetes Mellitus Affects Response to Neoadjuvant Chemoradiotherapy in the Management of Rectal Cancer Ann. Surg. Oncol., July 1, 2008; 15(7): 1931 - 1936. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. N. Baxter and J. Garcia-Aguilar Organ Preservation for Rectal Cancer J. Clin. Oncol., March 10, 2007; 25(8): 1014 - 1020. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. Maretto, F. Pomerri, S. Pucciarelli, C. Mescoli, E. Belluco, S. Burzi, M. Rugge, P. C. Muzzio, and D. Nitti The Potential of Restaging in the Prediction of Pathologic Response After Preoperative Chemoradiotherapy for Rectal Cancer Ann. Surg. Oncol., February 1, 2007; 14(2): 455 - 461. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. C. Harewood, S. Hoecht, W. Hinkelbein, J. W. Cromwell, L. T. Santiago, J. E. Marcet, G. Curigliano, G. Spitaleri, G. Zampino, J.-F. Bosset, et al. Treatment of rectal cancer. N. Engl. J. Med., December 7, 2006; 355(23): 2486 - 2486. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
